- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00472251
One-year Prospective Observational Study of BMI Change Effect of 5-alpha Reductase Inhibitor in Korean BPH Patients
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This study is a prospective, 1-year follow-up, observational study. We are planning to enroll 100 Korean patients with BPH. At each visit, patients' height, weight, abdominal circumference will be checked. Laboratory parameters including fasting glucose, HbA1c, serum testosterone, free testosterone, sex hormone-binding globulin, estradiol, maximum flow rate (measured by flowmetry) will be tested. Blood test will be performed twice (at baseline and at the end of study). 5mL of blood will be needed at each time from one subject. And total IPSS score will be evaluated after 1 year of treatment of 5 ARI. At every visit, use of above prohibited medicines and other medications will be investigated. In addition, any surgical procedures undertaken during study period will be asked and recorded.
Subjects of study will be allocated into 3 separate groups. Group 1 will be those taking 5 alpha reductase inhibitor (dutasteride) only for 1 year. Group2 will be those who switch from alpha blocker to dutasteride and take dutasteride for 1 year. Group 3 will be composed of those taking both alpha blocker and dutasteride for 1 year.
composed of
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Kyunggi-do
-
Seongnam-si, Kyunggi-do, Korea, republiek van, 463-707
- Seoul National University Bundang Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Male patients with symptomatic BPH
- Prostate volume of 30 cm3 or greater measured by transrectal ultrasound
- International Prostatic Symptom Score(IPSS) of 9 or greater
- Maximum urinary flow rate (Qmax) of 15ml/s or less
- No definite evidence of prostate cancer (on transrectal ultrasound, DRE, or etc.)
- Given Informed consent
Exclusion Criteria:
- Post-void residual more than 250 mL
- History of cancer (including prostate cancer) or previous prostatic surgery
- Acute urinary retention within 3 months of enrollment
- Chronic alcohol abuser and heavy smoker (> 10 cigarettes/day)
- History of/current drug abuse including laxatives
- Any previous 5 ARI administration
- Type 1 DM or Type 2 DM regardless of treatment
- Clinically significant endocrine diseases at investigator's discretion including thyroid diseases.
- History of /current bulimia or anorexia nervosa
- Regular use of following prohibited medicines within 3 months prior to screening; A. Medicines which can affect salt/water retention such as diuretics, calcium channel blockers, gabapentin, pregabalin, etc B. Medicines which can affect body weight such as sibutramine, orlistat, phentermine, amphetamine, etc.
C. Anti-thyroid medication, thyroxine, cyproheptadine, tranquilizers, systemic corticosteroids, testosterone supplement, or other medications that are known to affect body weight or BMI
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
body mass index
Tijdsspanne: after 1 year of treatment
|
after 1 year of treatment
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Sang Eun Lee, MD, PhD, Seoul National University Bundang Hospital
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CRT110446
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .